Both belong to the same drug class, glucagon-like peptide-1 (GLP-1) receptor agonists, but they offer subtle differences in their profiles
Notably, the risk appeared higher in trials studying weight loss indications, with higher doses, and with longer duration of treatment
Consulting with a Healthcare Provider Talking to a healthcare provider is crucial when deciding between tirzepatide and semaglutide
Though it's a relatively new treatment and devices aren't in every office, you can find a provider who has one here
Its a plausible hypothesis
The first includes injectable long-acting GLP-1R agonists and the second increases the bioavailability of endogenous GLP-1 by pharmacologically inhibiting dipeptidyl peptidase-4 (DPP-4), the enzyme that removes the N-terminal amino acid and consequently inactivates GLP-1 [2]